Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. (Nasdaq: PGEN) is a pioneering biopharmaceutical company dedicated to discovering and developing next-generation gene and cellular therapies in the United States. Specializing in disease-modifying therapeutics, Precigen has been at the forefront of genetic engineering and synthetic biology solutions. The company excels in creating innovative therapies for some of the most challenging diseases in areas such as immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen's core technologies include:
- UltraVector® Platform: This platform incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs.
- UltraCAR-T® Cell Therapies: These therapies address limitations of conventional CAR-T therapies by improving in vivo CAR-T expansion and persistence, adding safety features, and reducing manufacturing costs.
- AdenoVerse™ Technology Platform: A library of engineered adenovector serotypes, including gorilla adenovectors, which is used for gene delivery, and modulating immune responses.
- RheoSwitch® Inducible Gene Switch: This technology allows for precise control over gene expression, making therapies safer and more efficient.
Recent achievements include the Phase 2 pivotal study data for PRGN-2012 in treating recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. The study showcased promising results, with 51% of patients achieving Complete Response, defined as no need for surgical interventions in the 12-month period following treatment.
Precigen is also actively developing UltraCAR-T therapies, which have demonstrated significant preliminary efficacy and safety advantages over existing CAR-T therapies. These therapies are currently being evaluated in clinical trials for various hematological and solid tumors.
Financially, Precigen has shown resilience, focusing on sound fiscal management while advancing its clinical pipeline. Despite experiencing fluctuations in research expenses and revenues, the company remains committed to achieving its milestones and maintaining a strong balance sheet.
Precigen's business model involves commercializing its technologies through collaborations with industry partners who possess specialized expertise, development resources, and sales capabilities. This collaborative approach enables Precigen to bring new and improved products to market efficiently.
For the latest updates on Precigen's innovative gene and cell therapies, visit their official website and follow them on social media platforms like X (formerly Twitter), LinkedIn, and YouTube.
Precigen, a biopharmaceutical company, announced that the FDA granted orphan drug designation for its investigational immunotherapy PRGN-2012, aimed at treating recurrent respiratory papillomatosis (RRP). This designation provides access to various incentives that may expedite development and commercialization. PRGN-2012, developed in collaboration with the National Cancer Institute, utilizes gorilla adenovector technology to prompt immune responses against HPV 6 and 11. The condition affects a small population, making novel treatments critically needed. CEO Helen Sabzevari emphasized the urgency for new therapies.
Precigen, Inc. (Nasdaq: PGEN) announced its financial results for Q4 and the full year 2020, reporting total revenues of $103.2 million, up from $90.7 million in 2019. The company experienced a net loss of $103.8 million or $(0.62) per share. Despite challenges, Precigen raised $129.4 million from a public offering in January 2021, ensuring cash support through 2023. Key developments include promising preliminary clinical data for PRGN-3005 and PRGN-3006 UltraCAR-T therapies, paving the way for future trials.
Precigen, Inc. (Nasdaq: PGEN) will release its fourth quarter and full year 2020 financial results after market close on March 1, 2021. A conference call is scheduled for 4:30 PM ET that day to discuss the results and provide a business update. Helen Sabzevari, PhD, President and CEO, will also present at the H.C. Wainwright Virtual Global Life Sciences Conference starting March 9, 2021. The company is focused on advancing gene and cell therapies targeting serious diseases, with ongoing clinical trials and a commitment to innovation in therapeutics.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 12, 2021, at 11:30 AM ET. Investors can access the live webcast through Precigen's website in the Events & Presentations section. Precigen focuses on innovative gene and cell therapies targeting serious diseases, with an emphasis on immuno-oncology, autoimmune disorders, and infectious diseases. For more information, visit www.precigen.com.
Precigen (Nasdaq: PGEN) announced the successful closing of its public offering of common stock, selling 17,250,000 shares at $7.50 each, including an exercised option for 2,250,000 shares. The offering generated approximately $129.4 million in gross proceeds before expenses. Wells Fargo Securities and Stifel served as joint book-running managers, and the offering was made under an effective shelf registration statement. Precigen aims to advance gene and cell therapies in immuno-oncology and other areas.
Precigen, Inc. (PGEN) announced a public offering of 15 million shares at $7.50 per share, generating approximately $112.5 million in gross proceeds. The underwriters have a 30-day option to purchase an additional 2.25 million shares. The offering, expected to close on January 26, 2021, will fund clinical and preclinical product development, working capital, and other corporate purposes. Wells Fargo Securities and Stifel are joint book-running managers.
Precigen, a biopharmaceutical company (Nasdaq: PGEN), has initiated an underwritten public offering of its common stock, granting underwriters a 30-day option for additional shares. The offering, subject to market conditions, will be conducted under an effective shelf registration statement. The offering details, including size and terms, will be disclosed in a preliminary prospectus supplement to be filed with the SEC. Wells Fargo Securities and Stifel are the joint book-running managers for this offering.
On January 13, 2021, Precigen (Nasdaq: PGEN) presented its clinical achievements and goals at the 39th Annual J.P. Morgan Healthcare Conference. Highlights included updates on PRGN-3005 and PRGN-3006 UltraCAR-T, alongside the new UltraCAR-T library approach aimed at personalized cancer therapies. Preliminary data from the Phase I/II study of PRGN-2009 for treating HPV-associated cancers was shared, indicating a strong immune response in patients. The company also announced advancements in other AdenoVerse immunotherapies targeting RRP and HBV, emphasizing its commitment to innovative therapies amidst COVID-19 challenges.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 3:40 PM ET. She will also take part in a panel discussion on precision medicine at the H.C. Wainwright BioConnect 2021 Conference on the same day at 12:00 PM ET. Live webcasts are available on Precigen’s website. The company focuses on advancing gene and cell therapies, addressing major health challenges.
On January 5, 2021, Precigen (Nasdaq: PGEN) announced FDA clearance for its IND application to start a Phase I clinical trial for PRGN-2012, an investigational immunotherapy for recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV types 6 and 11. This trial aims to evaluate the safety and tolerability of PRGN-2012, which utilizes Precigen's proprietary gorilla adenovector technology. The study will enroll 12 patients to assess the treatment's efficacy following surgical removal of the disease. Precigen's collaboration with the NCI aims to address unmet medical needs in RRP patients.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
What does Precigen, Inc. specialize in?
What are some of Precigen's core technologies?
What are the key areas of focus for Precigen's therapies?
What recent achievements has Precigen made?
How does Precigen commercialize its technologies?
What makes UltraCAR-T® Cell Therapies unique?
What is the AdenoVerse™ Technology Platform?
Where can I find more information about Precigen's latest updates?
What financial strategies does Precigen employ?
What is the RheoSwitch® Inducible Gene Switch?
